Syncona Buys Out Ailing Gene Therapy Company Freeline
Syncona has stepped in to save Freeline and give it more time to prove the value of FLT201, its early-stage Gaucher’s disease gene therapy.
You may also be interested in...
Plus deals involving Bristol Myers Squibb/Avidity, Aexon/NLS, Boehringer Ingelheim/Phenomic AI, AnaptysBio/Centessa and Biodexa/Adhera/Melior.
AvroBio retains rights to its other HSC gene therapy candidates. Alimera Acquires Further Commercial Rights To Eyepoint’s Uveitis Drug.
Michael Parini talks to Scrip about how a new focus at the company can help it prove the value of its AAV-based gene therapy platform.